Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy - PubMed (original) (raw)
Review
Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy
Subramanian Selvamuthukumar et al. Lipids Health Dis. 2012.
Abstract
Nanotechnology having developed exponentially, the aim has been on therapeutic undertaking, particularly for cancerous disease chemotherapy. Nanostructured lipid carriers have attracted expanding scientific and commercial vigilance in the last couple of years as alternate carriers for the pharmaceutical consignment, particularly anticancer pharmaceuticals. Shortcomings often came across with anticancer mixtures, such as poor solubility, normal tissue toxicity, poor specificity and steadiness, as well as the high incidence rate of pharmaceutical resistance and the rapid degradation, need of large-scale output procedures, a fast release of the pharmaceutical from its carrier scheme, steadiness troubles, the residues of the organic solvents utilized in the output method and the toxicity from the polymer with esteem to the carrier scheme are anticipated to be overcome through use of the Nanostructured Lipid Carrier. In this review the benefits, types, drug release modulations, steadiness and output techniques of NLCs are discussed. In supplement, the function of NLC in cancer chemotherapy is presented and hotspots in research are emphasized. It is foreseen that, in the beside future, nanostructured lipid carriers will be further advanced to consign cytotoxic anticancer compounds in a more efficient, exact and protected manner.
Figures
Figure 1
SLN with high crystallinity and Different types of NLC. I – Highly imperfect matrix, II – Multiple O/F/W type, III – non-crystalline amorphous NLC.
Figure 2
Triggered pharmaceutical releases from NLC by starting the alteration from a highly disorganized lipid structure to more organized stable modifications.
Figure 3
Aggregation method in reduced intensified dispersions (upper) and pearl-like network in NLC dispersions with stabilizing effect.
Figure 4
Output of NLC Nanosuspension.
Similar articles
- Cancer chemotherapy with lipid-based nanocarriers.
Liu D, Zhang N. Liu D, et al. Crit Rev Ther Drug Carrier Syst. 2010;27(5):371-417. doi: 10.1615/critrevtherdrugcarriersyst.v27.i5.10. Crit Rev Ther Drug Carrier Syst. 2010. PMID: 21083528 Review. - Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
Qu J, Zhang L, Chen Z, Mao G, Gao Z, Lai X, Zhu X, Zhu J. Qu J, et al. Drug Deliv. 2016 Nov;23(9):3408-3416. doi: 10.1080/10717544.2016.1189465. Epub 2016 Jun 8. Drug Deliv. 2016. PMID: 27181462 - Nanostructured lipid carriers for site-specific drug delivery.
Khosa A, Reddi S, Saha RN. Khosa A, et al. Biomed Pharmacother. 2018 Jul;103:598-613. doi: 10.1016/j.biopha.2018.04.055. Epub 2018 Apr 24. Biomed Pharmacother. 2018. PMID: 29677547 Review. - Nanostructured Lipid Carriers: A Novel Platform for Chemotherapeutics.
Rizwanullah M, Ahmad J, Amin S. Rizwanullah M, et al. Curr Drug Deliv. 2016;13(1):4-26. doi: 10.2174/1567201812666150817124133. Curr Drug Deliv. 2016. PMID: 26279117 Review. - Size-exclusive effect of nanostructured lipid carriers on oral drug delivery.
Li H, Chen M, Su Z, Sun M, Ping Q. Li H, et al. Int J Pharm. 2016 Sep 10;511(1):524-537. doi: 10.1016/j.ijpharm.2016.07.049. Epub 2016 Jul 22. Int J Pharm. 2016. PMID: 27452421
Cited by
- Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers.
Gupta B, Poudel BK, Tran TH, Pradhan R, Cho HJ, Jeong JH, Shin BS, Choi HG, Yong CS, Kim JO. Gupta B, et al. Pharm Res. 2015 Sep;32(9):2912-27. doi: 10.1007/s11095-015-1673-7. Epub 2015 May 5. Pharm Res. 2015. PMID: 25939551 - Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA.
Shao Z, Shao J, Tan B, Guan S, Liu Z, Zhao Z, He F, Zhao J. Shao Z, et al. Int J Nanomedicine. 2015 Feb 11;10:1223-33. doi: 10.2147/IJN.S77837. eCollection 2015. Int J Nanomedicine. 2015. PMID: 25709444 Free PMC article. - RIPL peptide-conjugated nanostructured lipid carriers for enhanced intracellular drug delivery to hepsin-expressing cancer cells.
Lee SG, Kim CH, Sung SW, Lee ES, Goh MS, Yoon HY, Kang MJ, Lee S, Choi YW. Lee SG, et al. Int J Nanomedicine. 2018 Jun 1;13:3263-3278. doi: 10.2147/IJN.S166021. eCollection 2018. Int J Nanomedicine. 2018. PMID: 29910614 Free PMC article. - Surface Plasmon Resonance as a Characterization Tool for Lipid Nanoparticles Used in Drug Delivery.
Chain CY, Daza Millone MA, Cisneros JS, Ramirez EA, Vela ME. Chain CY, et al. Front Chem. 2021 Jan 7;8:605307. doi: 10.3389/fchem.2020.605307. eCollection 2020. Front Chem. 2021. PMID: 33490037 Free PMC article. Review. - Nanostructured lipid carriers loaded with tributyrin as an alternative to improve anticancer activity of all-trans retinoic acid.
Silva EL, Carneiro G, Caetano PA, Goulart G, Ferreira Costa D, de Souza-Fagundes EM, Gomes DA, Ferreira LA. Silva EL, et al. Expert Rev Anticancer Ther. 2015 Feb;15(2):247-56. doi: 10.1586/14737140.2015.1000868. Expert Rev Anticancer Ther. 2015. PMID: 25611812 Free PMC article.
References
- Gregoriadis G, Florence AT, Patel HM. In: Drug Targeting and Delivery. Florence AT, Chur GG, editor. Harwood Academic Publishers GmbH; 1993. Liposomes in drug delivery.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources